Ute Hennrich

1.4k total citations · 3 hit papers
12 papers, 1.1k citations indexed

About

Ute Hennrich is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ute Hennrich has authored 12 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Radiology, Nuclear Medicine and Imaging, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in Ute Hennrich's work include Radiopharmaceutical Chemistry and Applications (6 papers), Prostate Cancer Treatment and Research (6 papers) and Peptidase Inhibition and Analysis (3 papers). Ute Hennrich is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (6 papers), Prostate Cancer Treatment and Research (6 papers) and Peptidase Inhibition and Analysis (3 papers). Ute Hennrich collaborates with scholars based in Germany, Netherlands and United States. Ute Hennrich's co-authors include Klaus Kopka, Matthias Eder, Martina Benešová, Ulrike Bauder‐Wüst, Michael Eisenhut, Martin Schäfer, Oliver Neels, Uwe Haberkorn, Miriam Müller and Ali Afshar‐Oromieh and has published in prestigious journals such as Theranostics, Bioorganic & Medicinal Chemistry and Pharmaceuticals.

In The Last Decade

Ute Hennrich

11 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer

2014 317 citations Matthias Eder, Oliver Neels et al. Pharmaceuticals profile →
Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

2019 295 citations Ute Hennrich, Klaus Kopka Pharmaceuticals profile →
[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer

2022 171 citations Ute Hennrich, Matthias Eder Pharmaceuticals profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ute Hennrich Germany	8	717	474	436	195	181	12	1.1k
Sally W. Schwarz United States	16	957 1.3×	330 0.7×	362 0.8×	177 0.9×	123 0.7×	42	1.2k
Annemarie Eek Netherlands	19	692 1.0×	241 0.5×	501 1.1×	325 1.7×	279 1.5×	28	1.2k
Mickaël Bourgeois France	22	648 0.9×	200 0.4×	319 0.7×	97 0.5×	189 1.0×	45	996
Ingo Klette Germany	12	1.1k 1.5×	842 1.8×	458 1.1×	173 0.9×	129 0.7×	21	1.3k
Kwamena E. Baidoo United States	29	1.4k 1.9×	642 1.4×	537 1.2×	111 0.6×	271 1.5×	51	1.8k
Hazel B. Breitz United States	24	1.2k 1.7×	325 0.7×	486 1.1×	195 1.0×	271 1.5×	54	1.7k
Tomoya Uehara Japan	25	1.0k 1.4×	408 0.9×	567 1.3×	172 0.9×	285 1.6×	87	1.5k
Tom Bäck Sweden	28	1.8k 2.4×	756 1.6×	450 1.0×	100 0.5×	158 0.9×	71	2.0k
Eleni Gourni Germany	18	612 0.9×	306 0.6×	653 1.5×	127 0.7×	187 1.0×	42	1.2k
Irina Velikyan Sweden	15	736 1.0×	237 0.5×	413 0.9×	142 0.7×	185 1.0×	29	982

Countries citing papers authored by Ute Hennrich

Since Specialization

Citations

This map shows the geographic impact of Ute Hennrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ute Hennrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ute Hennrich more than expected).

Fields of papers citing papers by Ute Hennrich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ute Hennrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ute Hennrich. The network helps show where Ute Hennrich may publish in the future.

Co-authorship network of co-authors of Ute Hennrich

This figure shows the co-authorship network connecting the top 25 collaborators of Ute Hennrich. A scholar is included among the top collaborators of Ute Hennrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ute Hennrich. Ute Hennrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Hennrich, Ute, et al.. (2025). Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents. Pharmaceuticals. 18(6). 906–906.

Hennrich, Ute & Matthias Eder. (2022). [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals. 15(10). 1292–1292. 171 indexed citations breakdown →

Kopka, Klaus, et al.. (2021). Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer. Pharmaceuticals. 14(3). 188–188. 5 indexed citations

Hennrich, Ute & Matthias Eder. (2021). [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals. 14(8). 713–713. 102 indexed citations

Hennrich, Ute & Martina Benešová. (2020). [68Ga]Ga-DOTA-TOC: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging. Pharmaceuticals. 13(3). 38–38. 118 indexed citations

Neels, Oliver, et al.. (2019). Initiierung klinischer Multicenter-Studien mit lokaler Radiotracer-Herstellung. Nuklearmedizin - NuclearMedicine. 58(2). 77–85. 4 indexed citations

Hennrich, Ute & Klaus Kopka. (2019). Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. Pharmaceuticals. 12(3). 114–114. 295 indexed citations breakdown →

Eder, Matthias, Oliver Neels, Miriam Müller, et al.. (2014). Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals. 7(7). 779–796. 317 indexed citations breakdown →

Hennrich, Ute, Lisa Seyler, Martin Schäfer, et al.. (2012). Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression. Bioorganic & Medicinal Chemistry. 20(4). 1502–1510. 24 indexed citations

10.

Braun, Klaus, Marcel Beining, Manfred Wießler, et al.. (2012). BioShuttle Mobility in Living Cells Studied with High-Resolution FCS & CLSM Methodologies. International Journal of Medical Sciences. 9(5). 339–352. 5 indexed citations

11.

Pipkorn, Rüdiger, Manfred Wießler, Waldemar Waldeck, et al.. (2012). Improved Synthesis Strategy for Peptide Nucleic Acids (PNA) appropriate for Cell-specific Fluorescence Imaging. International Journal of Medical Sciences. 9(1). 1–10. 14 indexed citations

12.

Wießler, Manfred, Ute Hennrich, Rüdiger Pipkorn, et al.. (2011). Theranostic cRGD-BioShuttle Constructs Containing Temozolomide- and Cy7 For NIR-Imaging and Therapy. Theranostics. 1. 381–394. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact